China NT Pharma Group Company Limited (1011.HK)

HKD 0.27

(1.89%)

Total Debt Summary of China NT Pharma Group Company Limited

China NT Pharma Group Company Limited's latest annual total debt in 2023 was 344.94 Million CNY , down -58.26% from previous year.
China NT Pharma Group Company Limited's latest quarterly total debt in 2024 Q2 was 356.13 Million CNY , down 0.0% from previous quarter.
China NT Pharma Group Company Limited reported annual total debt of 826.45 Million CNY in 2022, down -0.68% from previous year.
China NT Pharma Group Company Limited reported annual total debt of 832.11 Million CNY in 2021, down -2.27% from previous year.
China NT Pharma Group Company Limited reported quarterly total debt of 852.71 Million CNY for 2023 Q2, down 0.0% from previous quarter.
China NT Pharma Group Company Limited reported quarterly total debt of 344.94 Million CNY for 2023 FY, down -58.26% from previous quarter.

Annual Total Debt Chart of China NT Pharma Group Company Limited (2023 - 2010)

Historical Annual Total Debt of China NT Pharma Group Company Limited (2023 - 2010)

Year	Total Debt	Total Debt Growth
2023	344.94 Million CNY	-58.26%
2022	826.45 Million CNY	-0.68%
2021	832.11 Million CNY	-2.27%
2020	851.45 Million CNY	-17.14%
2019	1.02 Billion CNY	1.69%
2018	1.01 Billion CNY	54.03%
2017	656.05 Million CNY	-26.49%
2016	892.44 Million CNY	241.71%
2015	261.17 Million CNY	-60.68%
2014	664.24 Million CNY	6.27%
2013	625.03 Million CNY	14.44%
2012	546.17 Million CNY	3.78%
2011	526.25 Million CNY	-37.36%
2010	840.18 Million CNY	0.0%

Year	Total Debt	Total Debt Growth
2024 Q2	356.13 Million CNY	0.0%
2023 Q2	852.71 Million CNY	0.0%
2023 FY	344.94 Million CNY	-58.26%
2023 Q4	344.94 Million CNY	0.0%
2022 Q2	826.26 Million CNY	0.0%
2022 FY	826.45 Million CNY	-0.68%
2022 Q4	826.45 Million CNY	0.0%
2021 Q2	730.5 Million CNY	0.0%
2021 Q4	832.11 Million CNY	0.0%
2021 FY	832.11 Million CNY	-2.27%
2020 FY	851.45 Million CNY	-17.14%
2020 Q2	989.42 Million CNY	0.0%
2020 Q4	851.45 Million CNY	0.0%
2019 Q2	998.07 Million CNY	0.0%
2019 FY	1.02 Billion CNY	1.69%
2019 Q4	1.02 Billion CNY	0.0%
2018 Q2	599.35 Million CNY	0.0%
2018 FY	1.01 Billion CNY	54.03%
2018 Q4	1.01 Billion CNY	0.0%
2017 FY	656.05 Million CNY	-26.49%
2017 Q2	778.41 Million CNY	0.0%
2017 Q4	656.05 Million CNY	0.0%
2016 FY	892.44 Million CNY	241.71%
2016 Q4	892.44 Million CNY	0.0%
2016 Q2	323.98 Million CNY	0.0%
2015 Q4	261.17 Million CNY	0.0%
2015 FY	261.17 Million CNY	-60.68%
2015 Q2	310.88 Million CNY	0.0%
2014 Q4	664.24 Million CNY	0.0%
2014 Q2	642.44 Million CNY	0.0%
2014 FY	664.24 Million CNY	6.27%
2013 Q4	625.03 Million CNY	0.0%
2013 FY	625.03 Million CNY	14.44%
2013 Q2	762.95 Million CNY	0.0%
2012 Q2	770.64 Million CNY	0.0%
2012 Q4	546.17 Million CNY	0.0%
2012 FY	546.17 Million CNY	3.78%
2011 Q4	526.25 Million CNY	0.0%
2011 Q2	774.57 Million CNY	0.0%
2011 FY	526.25 Million CNY	-37.36%
2010 Q4	840.18 Million CNY	0.0%
2010 FY	840.18 Million CNY	0.0%

Peer Total Debt Comparison of China NT Pharma Group Company Limited

Name	Total Debt	Total Debt Difference
Pak Fah Yeow International Limited	6.8 Million HKD	-4965.228%
Grand Pharmaceutical Group Limited	3.4 Billion HKD	89.867%
Extrawell Pharmaceutical Holdings Limited	120.41 Million HKD	-186.473%
Wai Yuen Tong Medicine Holdings Limited	460.94 Million HKD	25.167%
Qianhai Health Holdings Limited	487 Thousand HKD	-70729.979%
Lee's Pharmaceutical Holdings Limited	204.14 Million HKD	-68.973%
Essex Bio-Technology Limited	294.02 Million HKD	-17.318%
Tongfang Kontafarma Holdings Limited	333.82 Million HKD	-3.331%
PuraPharm Corporation Limited	424.77 Million HKD	18.793%
SSY Group Limited	3.37 Billion HKD	89.777%
JBM (Healthcare) Limited	133.4 Million HKD	-158.564%
Jacobson Pharma Corporation Limited	749.37 Million HKD	53.97%
China Resources Pharmaceutical Group Limited	85.84 Billion HKD	99.598%